Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

diabetic nephropathies/protease

Ссылка сохраняется в буфер обмена
Страница 1 от 119 полученные результаты

Diabetic nephropathy is associated with increased urine excretion of proteases plasmin, prostasin and urokinase and activation of amiloride-sensitive current in collecting duct cells.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
BACKGROUND Diabetic nephropathy (DN) is associated with hypertension, expanded extracellular volume and impaired renal Na(+) excretion. It was hypothesized that aberrant glomerular filtration of serine proteases in DN causes proteolytic activation of the epithelial sodium channel (ENaC) in the

Protease activated receptor 2 in diabetic nephropathy: a double edged sword.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Diabetic nephropathy is a major microvascular complication of diabetes mellitus, and the leading cause of end stage renal disease worldwide. The pathogenesis of diabetic nephropathy is complex, making the development of novel treatments that stop or reverse the progression of microalbuminuria into

Up-regulation of protease-activated receptor-1 in diabetic glomerulosclerosis.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Patients with diabetes are under a hypercoagulable state leading to generation of thrombin. It is not known whether thrombin plays a role in the progression of diabetic nephropathy. We analyzed gene expression of two thrombin receptors, protease-activated receptor-1 (PAR-1) and PAR-4 in the kidney

Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Endogenously administered activated protein C ameliorates diabetic nephropathy (DN) in a protease-activated receptor-1 (PAR-1)-dependent manner, suggesting that PAR-1 activation limits the progression of DN. Activation of PAR-1 in fibroblast-like cells, however, induces proliferation and

Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Diabetic nephropathy (DN) is one of the major complications of diabetes mellitus (DM), leads to chronic kidney disease (CKD), and, ultimately, is the main cause for end-stage kidney disease (ESKD). Beyond urinary albumin, no reliable biomarkers are available for accurate early diagnostics. Urinary

Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Mechanisms underlying the onset and progression of nephropathy in diabetic patients are not fully elucidated. Deregulation of proteolytic systems is a known path leading to disease manifestation, therefore we hypothesized that proteases aberrantly expressed in diabetic nephropathy (DN) may be

Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The role of hypercoagulability in the pathogenesis of diabetic nephropathy (DN) remains elusive. We recently reported the increased infiltration of macrophages expressing tissue factor in diabetic kidney glomeruli; tissue factor activates coagulation factor X (FX) to FXa, which in turn stimulates

Dual blockade of protease-activated receptor 1 and 2 additively ameliorates diabetic kidney disease.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Protease-activated receptors (PARs) are coagulation protease targets, and they increase expression of inflammatory cytokines and chemokines in various diseases. Of all PARs, previous reports show that PAR1 or PAR2 inhibition is protective against diabetic glomerular injury. However, how PAR1 and

Erratum: Protease activated receptor 2 in diabetic nephropathy: a double edged sword.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
[This corrects the article on p. 4512 in vol. 9, PMID: 29118913.].

Proteolysis of insulin-like growth factor-binding protein-3 is increased in urine from patients with diabetic nephropathy.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The insulin-like growth factor (IGF) system has been implicated in the development of experimental diabetic nephropathy. IGF-binding protein-3 (IGFBP-3) modulates IGF actions, and proteolysis decreases its binding affinity for IGFs. The aim of this study was to explore the possibility that

PAPP-A in normal human mesangial cells: effect of inflammation and factors related to diabetic nephropathy.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Insulin-like growth factors (IGFs) are implicated in the development of diabetic nephropathy (DN) and are shown to increase proliferation and extracellular matrix production in mesangial cells. The IGF system is complex and is composed of ligands, receptors, six binding proteins (IGF BPs) and a

Plasmin reduces fibronectin deposition by mesangial cells in a protease-activated receptor-1 independent manner.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
UNASSIGNED Protease-activated receptor-1 (PAR-1) potentiates diabetic nephropathy (DN) as evident from reduced kidney injury in diabetic PAR-1 deficient mice. Although thrombin is the prototypical PAR-1 agonist, anticoagulant treatment does not limit DN in experimental animal models suggesting that

Proteomic and metabolomic characterization of streptozotocin-induced diabetic nephropathy in TIMP3-deficient mice.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
OBJECTIVE The tissue inhibitor of metalloproteinase TIMP3 is a stromal protein that restrains the activity of both protease and receptor in the extracellular matrix and has been found to be down-regulated in diabetic nephropathy (DN), the leading cause of end-stage renal disease in developed

Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Diabetic nephropathy is the most common cause of end-stage renal failure. The primary glomerular changes in diabetic nephropathy are diffuse and nodular glomerulosclerosis, manifested by an increase in mesangial matrix. Research has demonstrated that advanced glycation end products (AGEs), oxidative

Protease-activated receptor 2 protects against VEGF inhibitor-induced glomerular endothelial and podocyte injury.

Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Vascular endothelial growth factor (VEGF) inhibitors cause glomerular injury. We have recently shown that activation of protease-activated receptor 2 (PAR2) by factor Xa exacerbated diabetic kidney disease. However, the role of PAR2 in glomerular injury induced by VEGF blockade is not known. Herein,
Присоединяйтесь к нашей
странице facebook

Самая полная база данных о лекарственных травах, подтвержденная наукой

  • Работает на 55 языках
  • Травяные лекарства, подтвержденные наукой
  • Распознавание трав по изображению
  • Интерактивная карта GPS - отметьте травы на месте (скоро)
  • Прочтите научные публикации, связанные с вашим поиском
  • Ищите лекарственные травы по их действию
  • Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов

Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.

Google Play badgeApp Store badge